SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-007890
Filing Date
2022-05-05
Accepted
2022-05-05 16:41:35
Documents
68
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q aldx-20220331.htm   iXBRL 10-Q 2018438
2 EX-31.1 aldx-ex31_1.htm EX-31.1 17937
3 EX-31.2 aldx-ex31_2.htm EX-31.2 18298
4 EX-32.1 aldx-ex32_1.htm EX-32.1 15367
  Complete submission text file 0000950170-22-007890.txt   6690767

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT aldx-20220331_def.xml EX-101.DEF 139347
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT aldx-20220331_pre.xml EX-101.PRE 263701
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT aldx-20220331.xsd EX-101.SCH 43654
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT aldx-20220331_cal.xml EX-101.CAL 42130
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT aldx-20220331_lab.xml EX-101.LAB 359192
62 EXTRACTED XBRL INSTANCE DOCUMENT aldx-20220331_htm.xml XML 1076244
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36332 | Film No.: 22897112
SIC: 2834 Pharmaceutical Preparations